Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Exchanging hands for $366, the stock is up 33% in 12 months and 16% in 2025. In the first quarter, it reported a revenue of $9.5 billion, up 10% year-over-year, and an EPS of $2.58, up 8% year ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) ... The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, ...

Eli Lilly and Company traded as low as $812.03 and last traded at $821.39. 747,819 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 3,467,154 shares ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

Eli Lilly CEO Dave Ricks on Thursday said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. Stream Los ...